|Bid||227.46 x 800|
|Ask||227.66 x 800|
|Day's range||224.41 - 230.00|
|52-week range||203.37 - 460.21|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||27.18|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
WILMINGTON, Mass. & MACCLESFIELD, England, June 28, 2022--Charles River announces the opening of their High Quality Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park.
WILMINGTON, Mass. & GHENT, Belgium, June 23, 2022--Charles River and Ziphius Vaccines collaborate to deliver early-stage clinical supply of plasmid DNA for saRNA-based vaccine program.
WILMINGTON, Mass., June 13, 2022--Charles River and ASC Therapeutics announce expanded relationship to scale manufacturing for a second generation gene therapy for hemophilia A.